KalVista Pharmaceuticals, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDKalVista Pharmaceuticals, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 3% provides fundamental context to the price action. However, with RSI at 76, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $26.86 | +0.53% | ABOVE |
| 50 SMA | $24.01 | +12.45% | ABOVE |
| 100 SMA | $20.06 | +34.58% | ABOVE |
| 150 SMA | $18.26 | +47.83% | ABOVE |
| 200 SMA | $16.84 | +60.30% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KALV in an uptrend right now?
KALV has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KALV is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KALV overbought or oversold?
KALV's RSI (14) is 76. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is KALV outperforming the market?
KALV has a Relative Strength (RS) Rating of 94 out of 99. Yes, KALV is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is KALV in its 52-week range?
KALV is trading at $27.00, which is 100% of its 52-week high ($27.00) and 100% above its 52-week low ($9.83).
How volatile is KALV?
KALV has a Beta of 0.69 and 52-week volatility of 73%. It's less volatile than the S&P 500 - generally more stable.